KSQ Therapeutics to present data at AACR 2022

By The Science Advisory Board staff writers

March 25, 2022 -- KSQ Therapeutics will give an oral presentation at the upcoming American Association for Cancer Research (AACR) 2022 annual meeting, held April 8-13.

The company will provide an overview of preclinical data on KSQ-4279, its USP1 inhibitor, as part of the ongoing phase I clinical trial of KSQ-4279 in advanced solid tumors.

USP1 was identified by KSQ's CRISPRomics platform as a novel synthetic lethal target in cancers with certain types of genomic instability, the company said.

The company's presentation will be on April 12 at 1:05-1:20 p.m. CT.

KSQ Therapeutics, Takeda to develop novel cancer immunotherapies
KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based...

Copyright © 2022 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter